The synergy of linagliptin and empagliflozin in catering to diabetes mellitus in Pakistan
Abstract
Diabetes is rapidly increasing globally, especially in lowand middle-income countries, with Pakistan ranking third in prevalence, having 33 million people. The lack of adherence to the first-line treatment, metformin, mainly due to gastrointestinal side effects, is a significant concern. A novel approach for managing type 2 diabetes in Pakistan is to combine linagliptin and empagliflozin. Linagliptin is well-tolerated and suitable for those who cannot tolerate metformin, while empagliflozin reduces cardiovascular risks and nephropathy, showing promising results in controlling diabetes with minimal side effects. The synergy between linagliptin and empagliflozin could greatly improve diabetes management and patient wellbeing. It is recommended that healthcare providers in Pakistan use social media and seminars to educate the public on this new treatment option to tackle the diabetes crisis effectively.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.